High lethality rate of carbapenem-resistant Acinetobacter baumannii in Intensive Care Units of a Brazilian hospital: An epidemiologic surveillance studyABSTRACT
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) is a growing threat to public health.
Methods: A 3-year retrospective study was conducted to evaluate the prevalence and lethality of multidrug-resistant (MDR) A. baumannii isolated from Brazilian patients.
Results: In this study, 219 Acinetobacter baumannii isolates were identified, of which 70.8% (155/219) were isolated from patients hospitalized in intensive care units. Of these, 57.4% (n = 89/155) were assessed, of which 92.1% (82/89) were carbapenem-resistant, and 49 were classified as infected. The lethality rate was 79.6% (39/49).
Conclusions: We highlight the need of an effective epidemiological surveillance measure to contain the dissemination of CRAB in the hospital environment.
Keywords: Acinetobacter baumannii; Carbapenem-resistant; Epidemiology; Surveillance; Lethality
Acinetobacter baumannii is widely recognized as an opportunistic pathogen in medical clinics, with the ability to colonize and infect hospital patients or discharged patients1. It also increases the risk of disseminating multidrug-resistant (MDR) microorganisms and interferes with the safety and quality of inpatient treatment2. The widespread and prolonged use of broad-spectrum antibiotics favors selective pressure, contributing to the emergence of MDR A. baumannii and restricting treatment options for infected patients. The excessive use of colistin as a last resort for therapy may have contributed to the increased number of A. baumannii resistant to colistin3. In 2017, A. baumannii was considered an alarming global health issue by the World Health Organization (WHO), which established its spread control as a priority4. Epidemiological studies on resistant bacteria may help formulate appropriate intervention plans for each hospital, thus reducing the spread of the pathogen in the nosocomial environment. In this 3-year retrospective study, we investigated the prevalence and lethality of MDR A. baumannii isolates from patients admitted to a Brazilian tertiary hospital.
This retrospective study was conducted at a tertiary hospital in Dourados, Brazil, from January 2015 to December 2017. Patients with A. baumannii isolated from clinical cultures were included in the study. Records with incomplete data, patients transferred to other hospitals prior to discharge from the intensive care unit (ICU), or were not monitored for loss of data or incorrect records, as well as records of the same patient with a different clinical source of infection, were excluded (Figure 1). For infectivity and lethality rates, we selected colonization or infection cases from all patients admitted to the ICU with A. baumannii isolates5. This study was approved by the Research Ethics Committee of Universidade Federal da Grande Dourados (no. 877.292/2014).
The clinical data of the patients admitted to the hospital were retrospectively analyzed. The following data were recorded: demographic characteristics, medical history, comorbidities, source of isolation, invasive procedures, mechanical ventilation, total parenteral nutrition, urinary catheter, drainage tube, nasogastric tube, tracheal intubation, treatment with immunosuppressive drugs, and source of infection. Clinical outcome (recovery/death) data were assessed. Septic shock was defined as sepsis associated with organ dysfunction accompanied by persistent hypotension after volume replacement (Table 1). The Centers for Disease Control and Prevention (CDC) definitions for colonization and infection were used to determine the association of isolated organisms. Colonization was defined as the presence of bacteria on a patient’s skin or mucous membranes, but dissociated from signs or symptoms of infectious disease. Infection was defined by medical diagnosis according to the clinical criteria associated with the use of antimicrobial therapy and isolation of resistant A. baumannii strain6. The infectivity index was calculated using the variation in the incidence of hospital infections caused by A. baumannii. An epidemic or outbreak was defined as a rate above the upper control limit, and the alert period was defined as a rate above the upper alert threshold7. The lethality rate was calculated using the following equation: (number of deaths due to an infection in a given area and period / total number of people infected in the same area and period) × 100.
Carbapenem-resistant A. baumannii (CRAB) isolates from patients admitted to the ICU of a tertiary hospital in Dourados/MS.
The study period included the outbreak investigation phase in 2015, the intervention phase in 2016, and the follow-up phase in 2017 at the ICUs. This investigation occurred after an increase in the incidence of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Intervention at the hospital occurred in June 2016, which established neonate contact isolation during the entire hospitalization period within the neonatal ICU, regardless of the culture outcome. Surveillance cultures were conducted from all patients hospitalized for more than 48 h in different wards, especially with the previous hospitalization. Limited sharing of patient equipment, hand hygiene promotion in the ICUs, general environmental cleaning, and disinfection with the biguanide-based solution of reusable medical equipment were properly executed. Cleaning of all surfaces, including walls, floors, furniture, ceilings, windows, and medical equipment, was intensified. The follow-up occurred with analysis throughout 2017 after implementing the hospital’s intervention plan to verify the effectiveness of the applied method, as the pathogen can survive and persist on surfaces, causing hospital outbreaks8.
Bacterial species were identified and tested for antimicrobial susceptibility using a BD PhoenixTM system (BD Biosciences, USA). The minimal inhibitory concentrations (MICs) were determined using the broth microdilution method following the Clinical and Laboratory Standards Institute Guidelines (CLSI)9. The antimicrobials tested included ampicillin/sulbactam, piperacillin/tazobactam, ceftazidime, ceftriaxone, cefepime, imipenem, meropenem, amikacin, gentamicin, ciprofloxacin, tigecycline, and colistin. American Type Culture Collection (ATCC®) Escherichia coli ATCC® 25922 and Pseudomonas aeruginosa ATCC® 27853 isolates were used as quality controls. Susceptibility was interpreted according to the CLSI9. The results are presented as frequency (percentage) to summarize the percentage ofA. baumanniicolonization and infection prevalence in clinical cultures, comorbidities, and outcomes among the ICUs observed in this study. Data were stored and analyzed using MS Excel XP® (Microsoft ®, Northampton, MA, USA).
In this study, 409 Acinetobacter spp. were identified in patients of a tertiary hospital in Dourados/MS, Brazil during the study period. Of these, 53.5% (219/409) were identified as A. baumannii, among which 70.8% (n = 155/219) were isolated from patients admitted to ICUs, 42.6% (n = 66/155) were classified as missing, and 57.4% (n = 89/155) were included. In addition, 92.1% (n = 82/89) of these isolates were resistant to carbapenems (Table 1) and were analyzed for infectivity and lethality rates. In August and October 2015, an increased peak of 41.6% (n = 37/82) of CRAB isolates was observed, followed by 33.7% (n = 30/82) in December 2017 and 24.7% (n = 22/82) in October 2016. CRAB isolates were most frequently isolated from males (58.5%, n = 48/82) and patients over 60 years of age (52.4%, n = 43/82). Adult ICU patients had a higher rate of CRAB (93.9%, n = 77/82). In addition, 47.6% (n = 39/82) of the CRAB isolates were isolated from tracheal aspirates, 31.7% (n = 26/82) from swabs, 8.6% (n = 7/82) from catheter tips, and 7.3% (n = 6/82) from blood cultures (Table 1). Among the patients, 63.4% (n = 52/82) had pneumonia, 43.9% (n = 36/82) had systemic arterial hypertension, 87.8% (n = 72/82) used delayed nasoenteric/bladder catheters, and 86.6% (n = 71/82) used invasive devices.
Regarding antimicrobial susceptibility, all CRAB isolates (n = 82) showed resistance to piperacillin/tazobactam (MIC50, ≥128 mg/L), cefepime (MIC50, ≥16 mg/L), and ciprofloxacin (MIC50, ≥4 mg/L); 98.8% (n = 81/82) to ceftriaxone (MIC50, ≥32 mg/L); 97.6% (n = 80/82) to ceftazidime (MIC50, ≥32 mg/L) and imipenem (MIC50, ≥8 mg/L); 93.9% (n = 77/82) to meropenem (MIC50, ≥8 mg/L); 90% (n = 74/82) to amikacin (MIC50, ≥32 mg/L-1); 87.8% (n = 72/82) to gentamicin (MIC50, ≥16 mg/L-1); and 15.9% (n = 13/82) to tigecycline (MIC50, ≥4 mg/L-1). However, all the isolates (n = 82) were susceptible to colistin (MIC50, ≥2 mg/L). In this study, 40% (n = 33/82) of CRAB isolates were considered colonized, whereas 60% (n = 49/82) were infected. Unfortunately, 39 patients died, representing a mortality rate of 79.6%. Data from adult ICUs showed endemic levels in August 2015, October 2015, and December 2017 (Figure 2). The infectivity plots for neonatal and pediatric ICUs were not elaborated because the number of patients admitted was insufficient.
Endemic level of colonization/infection due to carbapenem-resistant Acinetobacter baumannii isolates per 1000 patient-days from January 2015 to December 2017. Upper control limit (3σ + X); upper alert limit (2σ+ X); X: centerline (average rate of carbapenem-resistant A. baumannii per 1000 patient-days); 1, adult ICU.
Following the increase in endemic levels, measures to control the spread of MDR isolates were implemented, and a reduction in the incidence of CRAB was observed. In contrast, an increase in the endemic level was reported in December of the same year (Figure 2). Thus, despite the interventions, CRAB continued to spread. A similar result was reported previously for an outbreak of colistin-susceptible CRAB. This could be explained as overuse of antibiotics, and selective preassure was considered a cause for this scenario9. Although colistin could be a treatment option, the development and spread of resistant isolates in the hospital needed to be considered; thus, colistin should only be used as a last resort treatment.
MDR A. baumannii is considered a global problem owing to its dispersion and a challenge for hospital infection control services because of limited treatment options. The results of this study indicate a high prevalence of CRAB in ICUs. Risk factors such as prolonged hospitalization in ICUs, immunocompromised patients in critical condition, and invasive procedures favor the development of infection and a high prevalence of opportunistic bacteria such as A. baumannii in health facilities10. Following the national criteria for reporting healthcare-associated infections (HCAIs) defined by Agência Nacional de Vigilância Sanitária (ANVISA), which considers only cases that developed while the patient was in the ICU, we reported 59.75% (n = 49/82) cases in addition to the high prevalence of CRAB in ICU patients10. Usually, antibiotics are used extensively in developing countries, particularly in ICUs, resulting in a higher incidence of MDR and extensively drug-resistant bacteria combined with greater dissemination of these microorganisms11. Multidrug resistance is defined as non-susceptibility to at least one agent in three or more antimicrobial categories, whereas extensive drug resistance is defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (being susceptible to one or two categories)12. This is explained in part by the lack of resources and failure to implement control practices and prevention13. Moreover, comorbidities, such as pneumonia associated with mechanical ventilation, systemic arterial hypertension, diabetes mellitus, and renal failure, are associated with an increased risk of A. baumannii infection13.
In 2017, the distribution of carbapenem-resistant Acinetobacter spp. in blood infections in Brazil was 77.7% in adult ICUs, 48.6% in pediatric ICUs, and 33.3% in neonatal ICUs14. In our study, the CRAB isolates showed 100% resistance to piperacillin/tazobactam and ciprofloxacin. More than 95% of the isolates showed resistance to third-generation cephalosporins and carbapenems, and approximately 90% were resistant to aminoglycosides. The overuse of carbapenems in the hospital environment has been reported as a leading risk factor for increased bacterial resistance. Although some studies have reported a growing increase in colistin-resistant A. baumannii isolates, none were found in this study15.
In this study, CRAB isolates were more frequent in male patients (58.5%) and patients older than 60 years (52.4%)15. Although it is difficult to attribute the mortality rate to an underlying illness or the infection itself, we observed a high mortality rate associated with A. baumannii infection. Although the acquisition of CRAB isolates plays an important role in the high mortality rates, they are not the only risk factors responsible for the poor outcomes observed because the patients displayed several unfavorable clinical conditions15.
Furthermore, an increase in CRAB incidence was observed in August 2015, October 2015, and December 2017. Stringent infection control measures were introduced to prevent further spread, and the outbreak was declared to be under control in November 2015. However, our data showed that the control measures might have had a short-term effect, as they gradually lost efficacy in the following months. The number of new acquisitions of CRAB isolates started to increase in the ICUs, reaching the alert threshold in December 2017. Although active surveillance contributed to reducing the rates of this pathogen through control measures, our results highlighted the difficulty in eradicating this pathogen, indicating the possibility of selection and spread of clonal carbapenem-resistant isolates at a certain point. Additionally, control and containment of outbreaks are essential to reduce the impact of CRAB in the hospital environment.
However, the identification of isolates in this study was not confirmed by other techniques, such as MALDI-TOF and sequencing. We also highlight the importance of multicenter studies in Brazil for better comparison, comprehension, and validation of specific interventions in each hospital. Despite these limitations, this study showed a significant prevalence of CRAB isolates in a Brazilian hospital associated with a high mortality rate and difficulty in controlling the spread of CRAB in hospital wards. Epidemiological research may help monitor the dispersion of these isolates and contribute to the development of efficient infection control policies and containment intervention programs for this pathogen.
ACKNOWLEDGMENTS
We are grateful to the Universidade Federal da Grande Dourados (UFGD) and the research group in Molecular Biology of Microorganisms of this institution for their support.
REFERENCES
- 1 Schimith Bier KE, Luiz SO, Scheffer MC, Gales AC, Paganini MC, do Nascimento AJ, et al. Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil. Am J Infect Control. 2010;38(4):308-14.
- 2 Kurihara MNL, Sales RO, Silva KED, Maciel WG, Simionatto S. Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings. Rev Soc Bras Med Trop. 2020;53:e20200248.
- 3 Papathanakos G, Andrianopoulos I, Papathanasiou A, Priavali E, Koulenti D, Koulouras V. Colistin-ResistantAcinetobacter BaumanniiBacteremia: A Serious Threat for Critically Ill Patients. Microorganisms. 2020;8(2):287-99.
- 4 Gao L, Lyu Y, Li Y. Trends in drug resistance of Acinetobacter baumannii over a 10-year period: Nationwide data from the China surveillance of antimicrobial resistance program. Chin Med J (Engl). 2017;130(6):659-64.
- 5 Organização Pan-Americana da Saúde. Módulos de Princípios de Epidemiologia para o Controle de Enfermidades. Módulo 3: medida das condições de saúde e doença na população / Organização Pan-Americana da Saúde. Brasília: Organização Pan-Americana da Saúde; Ministério da Saúde; 2010. 94 p.
- 6 Casadevall A, Pirofski LA. Host-pathogen interactions: Basic concepts of microbial commensalism, colonization, infection, and disease. Infect Immun. 2000;68:6511-6518.
- 7 Arantes A, Carvalho EDS, Medeiros EAS, Farhat CK, Mantese OC. Use of statistical process control charts in the epidemiological surveillance of nosocomial infections. Rev Saude Publica. 2003;37(6):768-74.
- 8 Valencia-Martín R, Gonzalez-Galan V, Alvarez-Marín R, Cazalla-Foncueva AM, Aldabó T, Gil-Navarro MV, et al. A multimodal intervention program to control a long-termAcinetobacter baumanniiendemic in a tertiary care hospital. Antimicrob Resist Infect Control 2019;8(1):199-210.
- 9 World Health Organization (WHO). Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. World Health Organization; 2017. 45p.
- 10 Odewale G, Adefioye OJ, Ojo J, Adewumi FA, Olowe OA. Multidrug resistance of Acinetobacter baumannii in Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria. Eur J Microbiol Immunol. 2016;6(3):238-43.
- 11 Lynch JP, Zhanel GG, Clark NM. Infections Due to Acinetobacter baumannii in the ICU: Treatment Options. Semin Respir Crit Care Med. 2017;38(3):311-25.
- 12 Rocha IV, Xavier DE, Almeida KRH de, Oliveira SR de, Leal NC. Multidrug-resistant Acinetobacter baumannii clones persist on hospital inanimate surfaces. Brazilian J Infect Dis. 2018;22(5):438-41.
- 13 Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81.
-
14 ANVISA. Agência Nacional de Vigilância Sanitária. Boletim Segurança do Paciente e Qualidade em Serviços de Saúde nº 17: Avaliação dos indicadores nacionais das infecções relacionadas à assistência à saúde (IRAS) e resistência microbiana do ano de 2017 [updated 2017; cited 2021 July 20]. Available from: Available from: https://bit.ly/2Is5KPf
» https://bit.ly/2Is5KPf - 15 Palmieri M, D'Andrea MM, Pelegrin AC, Perrot N, Mirande C, Blanc B, et al. Abundance of Colistin-Resistant, OXA-23 and ArmA-ProducingAcinetobacter baumanniiBelonging to International Clone 2 in Greece. Front Microbiol. 2020;11:1-8.
-
Financial Support: Mariana Neri Lucas Kurihara, Romário Oliveira de Sales and Simone Simionatto received a scholarship from National Council for Science and Technological Development (CNPq) and Kesia Esther da Silva from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). The sponsors had no role in the collection, analysis and interpretation of data or the writing of the manuscript.
Publication Dates
-
Publication in this collection
29 Apr 2022 -
Date of issue
2022
History
-
Received
18 Sept 2021 -
Accepted
16 Feb 2022
